Greenline Partners LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,585 shares of the company’s stock after selling 120 shares during the quarter. Johnson & Johnson accounts for approximately 1.6% of Greenline Partners LLC’s holdings, making the stock its 21st biggest holding. Greenline Partners LLC’s holdings in Johnson & Johnson were worth $5,096,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of JNJ. Fisher Asset Management LLC grew its position in shares of Johnson & Johnson by 2.6% during the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after buying an additional 301,124 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of Johnson & Johnson by 0.5% in the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock worth $1,345,960,000 after acquiring an additional 48,582 shares during the period. Nordea Investment Management AB lifted its stake in shares of Johnson & Johnson by 14.2% in the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after acquiring an additional 1,079,751 shares during the period. Thoroughbred Financial Services LLC lifted its stake in shares of Johnson & Johnson by 14,147.0% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after acquiring an additional 3,986,071 shares during the period. Finally, Swedbank lifted its stake in shares of Johnson & Johnson by 5.5% in the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock worth $509,303,000 after acquiring an additional 209,665 shares during the period. Hedge funds and other institutional investors own 67.23% of the company’s stock.
In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at $419,040. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.23% of the stock is owned by corporate insiders.
Shares of NYSE:JNJ opened at $128.56 on Wednesday. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The firm has a market cap of $337.10 billion, a P/E ratio of 15.72, a P/E/G ratio of 2.16 and a beta of 0.69. The company has a 50 day moving average of $131.66 and a 200-day moving average of $136.44. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period in the prior year, the business earned $2.10 earnings per share. The business’s quarterly revenue was down 1.3% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.96%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What are CEFs?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.